 AUSTIN, Texas--BUSINESS WIRE--Savara Inc. Nasdaq: SVRA, an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of 1.45 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors pre-funded warrants t 